NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

You know this how?? Murcidencel certainly will depend on one regulatory agency as the U.S. oncology market is by far the most important revenue market. UK may get approval, but the UK single payer NICE will very likely have very limited coverage as they do with the other immunotherapies like CAR-T. They only cover 100 patients a year for Kite's CAR-T. Not much revenue potential.

There are also countless reason's to be concerned that the FDA will have issues with NWBO's dubious Phase 3 trial. FDA partial hold, confounding of naive OS, statistical manipulation to try to compensate for the confounding, double dosing murcidencel without screening external comparator trials for dosing frequency, post hoc, data dredged recurrent OS with n=64,